New Study Shows This Common OTC Pain Reliever Has a Really Scary Side Effect

Ibuprofen, a common over-the-counter pain reliever, has a troubling side-effect that’s often overlooked, but new findings have proved it’s more important to know about this now than ever before. Recent evidence found that non-steroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, can increase your chances of having a heart attack in as little as one week of continuous use.

In a recent study published in the British Medical Journal, data from almost 450,000 people, 61,460 of whom had suffered a heart attack, was analyzed looking for the effect over time of taking three common anti-inflammatory painkillers: ibuprofen, diclofenac and naproxen. The data revealed that compared with people who didn’t take the painkillers, those who did ingest them had a 20 percent to 50 percent increased risk of having a heart attack.

Additionally, the risk was found to be higher for people who ingested 1,200 mg a day of ibuprofen (about six tablets of Advil) and 750 mg a day for naproxen (about three and a half Aleves), Yahoo! reports. The study reported that it only took a week for a higher risk of heart attack to set in on a person, with the highest risk occurring at about a month of usage. After a month, researchers found that the risk didn’t increase further but rather stayed the same.

Typically, NSAIDs are safe when used correctly for mild pain relief, however, many people have begun relying on NSAIDs for prolonged periods of time at a higher dosage to treat their pain, which is why the risk of heart attack associated with the use of NSAIDs has begun to rise.

While this study certainly revealed a scary truth about the drug, it’s important to note that taking an NSAID for minor pain relief at the lowest effective dose and a minimal length of time isn’t likely to cause aheart attack. It’s the usage level over a longer time period at higher dosage that can be dangerous, so it’s best to limit your use as much as possible to avoid any unwanted negative side effects.





The New Filler That Will Completely Change Your Skin

Photo Credits: Model Used for Illustrative Purpose Only

The extremes women will go to get better skin are endless. Some of us slather on pricey skin care products, others treat their skin to regular facials, and a large majority head straight to the doctor’s office for the latest and greatest treatments and procedures.

But all of that may be changing as a new type of filler—yes, you read that right—makes its way on to our shores.

You May Also Like: The FDA Just Approved a New Filler That’s the First of Its Kind

For years, injectables and fillers have been heralded as the remedy for adding back lost volume to the face, filling in lines and wrinkles and even augmenting some facial features. Now, a new category of fillers known as skin boosters, which includes Juvéderm Volite, is on the horizon.

Although Volite is only available in Europe, it’s totally different from what you currently know fillers as in that it improves skin texture and elasticity. The fillers on the market right now address volume and not necessarily the skin.

Used in the face, hands, décolleté and neck, and injected into the top layer of skin, skin boosters work best on areas of skin that are covered in teeny, tiny lines, like the sides of the cheeks or the chin. “Injecting skin boosters causes bioremodeling of the skin, activating elastin and collagen production and improving the look of damaged or aged skin,” says New York plastic surgeon Haideh Hirmand, MD.

Injections need to be done three times and then again every six months, but the quality of the skin can dramatically change.

Stay tuned to for updates on this exciting new innovation!


Thousands of cancer patients dying in needless agony, new data reveals

Nursing holding hands with patient

Poorly coordinated care for those at home plays a large part CREDIT: PASCAL LACHENAUD/AFP

Thousands of cancer patients are dying in needless pain because of disjointed care for people who have returned home to be with loved ones, experts have warned.

New data reveals one in ten people who die of cancer have inadequate pain relief in their final 48 hours.

Charities have criticised the Office for National Statistics figures as “unacceptable”, and called on the Government to make good on its manifesto pledge to improve the standard of palliative care.

Macmillan Cancer Support, which conducted the analysis, said fears of uncontrollable pain were cancer patients’ top concern as they approached the end of life.

There’s no excuse for so many people with cancer still not getting the support they need at the end of their livesLynda Thomas, Macmillan Cancer Support

The organisation says 12,000 people who died from the disease in 2015 were not cared for properly in the final stages.

Many of these were outside hospital and reliant on community services such as visiting nurses to receive pain-relieving drugs.

The ONS statistics showed patients were four times more likely to die in pain at home than in hospital.

Macmillan said their research revealed that of the people who felt services had not worked properly when they had been treated at home, 72% also had poor pain relief.

Lynda Thomas, the charity’s chief executive, said: “There’s no excuse for so many people with cancer still not getting the support they need at the end of their lives.

“Absolutely no one should suffer unnecessary pain in their final days – with the right support this can be avoidable.

“We need better-coordinated, round-the-clock community care to help prevent this anguish.

The last year the Government committed to providing high quality end-of-life care to all patients regardless of location, a pledge that was repeated in the General Election manifesto.

“The Government must now make these promises a reality and end the variation in the quality of care people receive,” said Ms Thomas.

“Things cannot carry on the way they are.”

A Department of Health spokesperson said: “Cancer survival is at a record high and we are fully committed to improving cancer outcomes for everyone, including palliative care, which we know is not always good enough.

“That’s exactly why our strategy for achieving world-class cancer outcomes includes a clear commitment to ensure earlier access to palliative support, which we expect NHS England to deliver for patients.”


New Cancer Treatment Uses Patient’s Immune System To Fight Disease

Image result for New Cancer Treatment Uses Patient’s Immune System To Fight DiseaseNEW YORK (KDKA) – Scientists are reporting unprecedented success with a new type of cancer treatment. It uses the patient’s own immune system to fight the disease.

Emma Collins looks like a typical 16-year-old girl now, but less than three years ago she was dying of cancer.

Kashaun Lawhown, 7, was facing the same fate.

Both of them were battling leukemia, and traditional treatments — chemotherapy and radiation — weren’t working.

A game changing experimental cancer treatment that utilizes the body’s own immune system gave them a second chance.

“The immune system has developed over many, many billions of years to actually get rid of things that don’t belong in the body, cancer doesn’t belong there,” Dr. Stephan Grupp said.

Dr. Grupp is the Director of Immunotherapy at The Children’s Hospital of Philadelphia where Kashaun and Emma took part in a clinical trial for this revolutionary treatment.

“We collect white blood cells from the patient — those include T-cells. Those T-cells then go to a specific place where they are manufactured; reprogrammed to actually be able to attack cancer cells,” Dr. Grupp said.

These suped-up cells, now called CAR-T cells are then put back in the body where they multiply and get to work.

“When they find something that they recognize, like the B-cell leukemia, they kill that off,” Dr. Shannon Maude. said.

“If you had told me five years ago, how effective they would be, I wouldn’t have believed you,” Dr. Stephen Hunger said.

Better yet, some of the CAR T-Cells may actually stick around to fight a recurrence.

“A one-time treatment can certainly lead to at least five years of survival, and we hope can lead to cures,” Dr. Hunger said.

After battling leukemia for five years, it took just one T-cell treatment to finally put Kashaun’s cancer into remission.

“Everything worked out good and I’m healthy,” Emma said.

Just four days after her treatment there was no sign of her cancer. What’s more amazing, she’s been in remission now for 18 months.

Out of many, many years, or many, many people doing a lot of work to come to this point, it’s really exciting,” Dr. Maude said.

The CAR-T therapy is effective mainly against leukemia and lymphoma but researchers are working to also use it against so-called solid tumors like breast, colon, and lung.

Not all patients have their cancer destroyed, the trials have been positive enough that the FDA is expected to approve the therapy this year.


New blood test could see personalised prostate cancer treatment

The Institute of Cancer Research says blood tests for cancer promise to be truly revolutionary, as they are cheap and simple to use. Photograph: Elaine Thompson/AP

A new three-in-one blood test could pave the way to precision-personalised treatment for advanced prostate cancer, say scientists.

The test has the potential to transform the way the disease is tackled by targeting specific gene mutations, it is claimed.

By looking for cancer DNA in blood samples, researchers were able to identify men with defective BRCA genes who were likely to benefit from a class of drugs called Parp inhibitors.

They also used the test to monitor DNA in the blood after treatment started, so patients who were not responding could quickly be switched to an alternative therapy.

Finally, the same test was used to pick up signs of evolving cancer showing the first signs of drug resistance.

Prof Johann de Bono, who led the team at the Institute of Cancer Research in London, said: “We were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.

“We think it could be used to make clinical decisions about whether a Parp inhibitor is working within as little as four to eight weeks of starting therapy.

“Not only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.”

In future, the test could allow the Parp inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting those most likely to benefit, picking up early signs that the drug might not be working, and monitoring for emerging resistance.

Parp inhibitors such as olaparib block an enzyme used by cancer cells with defective BRCA 1 and 2 genes to repair their DNA.

When Parp is disabled, the cells die. The drugs do not generally work on cancer cells with functioning BRCA genes, because these are primary DNA repair tools that make Parp unnecessary. While some patients respond to the drugs for years, others either fail to respond at an early stage or develop resistant cancer.

The new test, described in the journal Cancer Discovery, was developed with the help of 49 patients enrolled in TOPARP-A, a Phase II clinical trial investigating the effectiveness of olaparib.

Men responding to the drug were found to experience an average drop in circulating cancer DNA of 49.6% after eight weeks of treatment. In contrast, cancer DNA levels rose by 2.1% in patients who did not respond.

Patients whose cancer DNA blood levels were lowered by olaparib survived an average of 17 months compared with 10.1 months for those whose levels remained high.

The scientists also conducted a detailed investigation of the genetic changes in cancer DNA among men who stopped responding to olaparib. They found that the cells acquired genetic changes that cancelled out the DNA repair defects making them susceptible to the drug.

Prof Paul Workman, chief executive of the Institute of Cancer Research, said: “Blood tests for cancer promise to be truly revolutionary. They are cheap and simple to use, but most importantly, because they aren’t invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing – offering patients the best chance of surviving their disease.

“This test is particularly exciting because it is multi-purpose, designed for use both before and after treatment, and using both the absolute amounts of cancer DNA in the bloodstream and also a readout of the specific mutations within that genetic material.

“We believe it can usher in a new era of precision medicine for prostate cancer.”

Each year, around 47,000 men in the UK are diagnosed with prostate cancer and more than 11,000 die from the disease.

Dr Matthew Hobbs, deputy director of research at the charity Prostate Cancer UK, which funded the research, said: “It’s clear that we need to move away from the current one-size-fits-all approach to much more targeted treatment methods.

“The results from this study and others like it are crucial as they give an important understanding of the factors that drive certain prostate cancers, or make them vulnerable to specific treatments.”


New OneDrive for iOS update brings support for animated GIF files

Microsoft has pushed out a new update to the iOS client of its OneDrive app. The update, which bumps the app to version 8.8.9, brings along several changes, including support for animated GIF files.

Aside from animated GIF support, the updated app now also lets you instantly switch accounts by tapping and holding on the Me tab. Those with work or school accounts will now receive notifications when someone shares a file with them.

Moving on, the update also includes support for Instant Preview in the Sites tab. And finally, some usual bug and crash fixes are also there. The updated app is now available for download from the App Store.


Windows 10’s Creators Update bug bash begins, signalling an end to new feature releases

windows 10 creators update bug bash

On Friday, Microsoft announced the launch of its “bug bash” for the Windows 10 Creators Update, a sign that it’s beginning to slowly wind down its development process before it finally releases the next major version of Windows.

Historically, Microsoft begins each iteration of its milestone Windows 10 releases by fixing a few last-minute bugs from the previous version. It then begins rolling out and testing all the new features of the upcoming milestone to Windows Insiders in the preview program.

At some point, though, Microsoft moves into the last phase of its development process, fixing all of the bugs that Microsoft employees and its Windows Insider beta testers discover in the imminent release. That phase typically begins with a huge bug-fixing exercise, known as the “bug bash,” whose current iteration will run through Feb. 11. Microsoft uses the information it gathers to determine which bugs are the most serious and prevalent, prioritizing them.

Microsoft hasn’t said when the Creators Update will actually ship; it’s still due in “early 2017.” The blog post announcing the bug bash notes that Microsoft developers will be working on fixing these bugs for the next “several weeks,” however, meaning that our guess that the Creators Update could be released at the end of March is still valid.

Why this matters: Most users know on some level that adding a new software feature introduces new bugs to go along with it. The annual bug bash/bug-fixing phase is critical, however, to help shape the public’s opinion. Not every bug will be found or eliminated before the software’s release. The idea is to at least prevent headline-grabbing glitches such as those that disabled webcams in the Anniversary Update.

How the Windows 10 CU bug bash works

Any motivation to assist Microsoft in its bug bash is primarily a charitable one, with the end goal of simply improving Windows. Nevertheless, Microsoft is offering special Bug Bash badges for the Feedback Hub as prizes for those that participate.

Insiders need to check the Windows 10 Feedback Hub for new “Quests,” tasks that Microsoft would like beta testers to perform to check for bugs. Leaving feedback within the Hub is also encouraged. You’ll need to make sure that you’re running the latest Windows 10 preview, Insider Build 15025, which includes a consolidated feedback mechanism so that similar reports are consolidated into a single response.

bug bash tweet

Ads by Kiosked

Jen Gentleman

Microsoft will also hold live webcasts with engineers from 2 through 4 P.M. PT on Feb. 7, and from 7 through 9 P.M. on Feb. 7, to walk users through some of the quests. Those quests will change over the course of the week, Microsoft said.

As always, we recommend that Insiders test out Windows 10 on a secondary PC, one that you don’t do anything truly important on. Stumbling across glitches or bugs that can break or force you to reset your PC is part of the Insider experience. Cruising on an Insider machine, though, can also be an awful lot of fun.


New Concept build for Sony Xperia X brings ambient display, other changes

As part of its Concept for Android program, Sony has pushed out a new update to participating Xperia X units. Arriving as version 38.3.A.0.94, the update brings along several changes, including ambient display.

The ambient display feature allows your phone screen to wake up whenever there’s a new notification. The feature can be enabled/disabled through the ‘Ambient display’ option in the device’s Settings menu.

Aside from this, the camera viewfinder now has a fixed brightness. As for bug fixes, the Bluetooth audio loss issue due to Ok Google has been fixed, so is the missed call LED problem as well as the tinted colors issue.


Plex’s new Amazon Echo support lets you control your home theater with your voice


Plex is getting into the home automation game. The popular media management software just announced it now has an Alexa skill, as well as smart home features that turns off the lights or post a message in Slack based on an action you take with Plex.

The new Alexa skill is available now in the US and UK Alexa stores. Once you’ve activated the Plex skill, you can ask your Alexa to play content from your local media library on demand, such as a movie or a television episode from a specific season. Not sure what you’re in the mood for? You can also ask Alexa and Plex (Plexa?) to suggest music or something to watch.

Plex doesn’t specifically say this, but it appears the Alexa skill is open to all users, not just Plex Pass subscribers.

Get smart

That said, the company is also adding an interesting new feature for Plex Pass users called Webhooks. Basically, what this means is that when you take an action with Plex, a secondary action can be carried out by a computer.

If you start a movie in Plex, for example, you could use Plex’s Webhooks feature to automatically dim the living room lights. Right now, Plex is hoping to get developers to start adding Webhooks that integrate with Plex.

The impact on you at home: There are three examples on Github that you can try out right now, including desktop notifications for music playback, automated Slack posts when you rate something in Plex, and a smart light integration with the Wink Hub.

These integrations are useful, but they’ll require some knowledge of JavaScript meaning it’s probably out of the grasp of most users, and that may not change. Plex’s technical documentation for Webhooks says they are a “fairly advanced feature and won’t commonly be used by an ‘average’ user.” Plex Pass Pro customers may be able to get an installer to come to their home and set Webhooks up, however.

This story, “Plex’s new Amazon Echo support lets you control your home theater with your voice” was originally published by TechHive.

To comment on this article and other PCWorld content, visit our Facebook page or our Twitter feed.


Father of Indian Supercomputer Vijay Pandurang Bhatkar becomes Nalanda University’s new vice-chancellor

Vijay Pandurang Bhatkar, 70, has been appointed as the new Vice-Chancellor of Nalanda University, Rajgir, in Bihar. President Pranab Mukherjee, in his capacity as visitor to Nalanda University, named Bhatkar for the post with effect from January 25.

Nalanda University gets a new vice-chancellor

Nalanda University gets a new vice-chancellor

  • Rajasthan: Chapter on demonetisation to be included in high school syllabus
  • UPSC CDS (I) 2016: Results declared at
  • NEET to be the soul criteria for selecting students for medical courses

Vijay Pandurang Bhatkar, 70, has been appointed as the new Vice-Chancellor of Nalanda University, Rajgir, in Bihar. He is a technocrat who is popularly known as the father of the Indian Supercomputer. He will hold the office for a three-year period from the date of his appointment as per the Nalanda University Act, Sec. 11(3).

Born on October 11, 1946 in Pune, Bhatkar was educated at IIT, Delhi, Sir Visvesvaraya National Institute of Technology, Nagpur and MS University, Vadodara. He has also been honoured with the Padma Shri and Padma Bhushan, the fourth and third highest civilian honours in India.

President Pranab Mukherjee, in his capacity as a  visitor to Nalanda University, named Bhatkar for the post with effect from January 25.

Bhatkar replaces Gopa Sabharwal who resigned on November 24 last year, followed by the resignation of Chancellor George Yeo, after the dissolution of the Mentor Group which functioned as the governing body of the university.

(Read: Patna: Civil servants to teach at schools)

He is known as the architect of India`s initiative in supercomputing, the Centre of Development of Advanced Computing (C-DAC) in Pune founded in 1988, leading to the development of the first indigenous supercomputer Param 8,000 in 1991, followed by Param 10,000 in 1998.

Established in November 2010 as a Central University, Nalanda University is spread over a 443-acres campus and started offering academic programmes in 2014. It is a dream project of Bihar Chief Minister Nitish Kumar. Various distinct international personalities like Nobel laureate Amartya Sen, George Yeo, former Foreign Minister of Singapore, Sugata Bose of Harvard University and other dignitaries have been involved with Nalanda University since its founding.